Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 24Burkitt Lymphoma 19Lymphoma, Follicular 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 6Recurrence 5Prostatic Neoplasms, Castration-Resistant 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Prostate Cancer Metastatic 2Plasmablastic Lymphoma 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

olaparib 3enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Pluvicto 2Docetaxel 2Androgen Antagonists 2Abiraterone Acetate 2testosterone 17 beta-cypionate 1radium Ra 223 dichloride 1fludarabine phosphate 1fludarabine 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Prednisone × 90 days × Clear all
NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

BioNTech SE

Phase 3 Recruiting
736 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡